Regeneron Historical Balance Sheet

REGN Stock

USD 754.87 1.84 0.24%

Trend analysis of Regeneron Pharmaceuticals balance sheet accounts such as Retained Earnings of 28.6 B, Cash of 2.9 B, Non Current Assets Total of 14.3 B or Non Currrent Assets Other of 384.4 M provides information on Regeneron Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Regeneron Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using Regeneron Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Regeneron Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Regeneron Pharmaceuticals is a good buy for the upcoming year.

Regeneron Pharmaceuticals Inventory

2.71 Billion

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regeneron Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.

About Regeneron Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Regeneron Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Regeneron Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Regeneron Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Regeneron currently owns. An asset can also be divided into two categories, current and non-current.

Regeneron Pharmaceuticals Balance Sheet Chart

At this time, Regeneron Pharmaceuticals' Non Current Assets Total are very stable compared to the past year. As of the 29th of November 2024, Non Currrent Assets Other is likely to grow to about 384.4 M, while Net Debt is likely to drop (28.5 M).

Total Assets Total Stockholder Equity Property Plant And Equipment Net Property Plant And Equipment Gross Capital Stock

Add Fundamental

Total Assets

Total assets refers to the total amount of Regeneron Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Regeneron Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Property Plant And Equipment Net

The total value of a company's physical assets (such as land, buildings, and equipment) used in operations, net of depreciation. It reflects the company's investment in assets used for production.

Capital Stock

The total amount of a company's capital funded by shareholders through the issue and subscription of shares.

Most accounts from Regeneron Pharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Regeneron Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regeneron Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.At this time, Regeneron Pharmaceuticals' Non Current Assets Total are very stable compared to the past year. As of the 29th of November 2024, Non Currrent Assets Other is likely to grow to about 384.4 M, while Net Debt is likely to drop (28.5 M).

	2021	2022	2023	2024 (projected)
Total Current Liabilities	3.5B	3.8B	3.4B	3.6B
Total Assets	25.4B	29.2B	33.1B	34.7B

Total Current Liabilities Total Assets

Regeneron Pharmaceuticals balance sheet Correlations

	Total Assets	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Intangible Assets	Short Long Term Debt Total	Other Current Liab	Accounts Payable	Short Term Debt	Property Plant And Equipment Gross	Short Term Investments	Inventory	Other Liab
Total Assets		0.97	1.0	0.95	-0.06	0.99	0.97	0.93	-0.25	0.96	0.98	0.15	0.95	0.26	-0.66	0.97	0.98	0.83	0.86	0.94	0.98	0.63	0.99	0.93	0.98	0.58
Total Current Liabilities	0.97		0.96	0.94	-0.03	0.95	0.99	0.84	-0.32	0.98	0.98	0.2	0.95	0.4	-0.66	0.99	0.99	0.73	0.92	0.89	0.99	0.72	0.97	0.83	0.98	0.56
Total Stockholder Equity	1.0	0.96		0.93	-0.09	0.99	0.95	0.94	-0.26	0.95	0.96	0.13	0.92	0.22	-0.67	0.95	0.97	0.85	0.83	0.95	0.96	0.6	0.99	0.94	0.97	0.56
Property Plant And Equipment Net	0.95	0.94	0.93		-0.16	0.9	0.93	0.88	-0.16	0.9	0.95	0.31	0.96	0.33	-0.45	0.96	0.93	0.69	0.84	0.83	0.95	0.71	0.97	0.82	0.96	0.78
Net Debt	-0.06	-0.03	-0.09	-0.16		0.0	-0.1	-0.01	0.13	-0.14	-0.01	-0.17	0.08	0.03	-0.49	0.02	-0.09	0.03	0.28	-0.16	-0.08	-0.08	-0.1	0.01	-0.06	-0.4
Retained Earnings	0.99	0.95	0.99	0.9	0.0		0.94	0.93	-0.28	0.95	0.96	0.05	0.91	0.21	-0.75	0.95	0.97	0.87	0.85	0.95	0.95	0.57	0.97	0.95	0.96	0.48
Cash	0.97	0.99	0.95	0.93	-0.1	0.94		0.82	-0.32	0.98	0.98	0.23	0.93	0.41	-0.62	0.98	0.99	0.71	0.9	0.89	0.98	0.72	0.95	0.82	0.97	0.54
Non Current Assets Total	0.93	0.84	0.94	0.88	-0.01	0.93	0.82		-0.09	0.8	0.86	0.07	0.88	0.09	-0.62	0.87	0.84	0.9	0.73	0.87	0.86	0.46	0.93	0.98	0.89	0.6
Non Currrent Assets Other	-0.25	-0.32	-0.26	-0.16	0.13	-0.28	-0.32	-0.09		-0.4	-0.22	-0.04	-0.07	0.03	0.27	-0.21	-0.33	-0.42	-0.22	-0.27	-0.23	0.06	-0.24	-0.17	-0.24	-0.01
Cash And Short Term Investments	0.96	0.98	0.95	0.9	-0.14	0.95	0.98	0.8	-0.4		0.97	0.18	0.89	0.34	-0.63	0.95	0.99	0.73	0.85	0.92	0.97	0.68	0.95	0.82	0.95	0.5
Net Receivables	0.98	0.98	0.96	0.95	-0.01	0.96	0.98	0.86	-0.22	0.97		0.22	0.97	0.32	-0.65	0.99	0.99	0.71	0.91	0.9	0.98	0.71	0.97	0.85	0.97	0.56
Common Stock Shares Outstanding	0.15	0.2	0.13	0.31	-0.17	0.05	0.23	0.07	-0.04	0.18	0.22		0.28	0.27	0.37	0.24	0.19	-0.07	0.21	0.06	0.21	0.26	0.2	-0.02	0.16	0.47
Non Current Liabilities Total	0.95	0.95	0.92	0.96	0.08	0.91	0.93	0.88	-0.07	0.89	0.97	0.28		0.4	-0.59	0.99	0.93	0.67	0.93	0.81	0.96	0.74	0.95	0.83	0.96	0.65
Other Current Assets	0.26	0.4	0.22	0.33	0.03	0.21	0.41	0.09	0.03	0.34	0.32	0.27	0.4		-0.09	0.4	0.34	-0.08	0.47	0.1	0.42	0.73	0.23	0.05	0.38	0.2
Other Stockholder Equity	-0.66	-0.66	-0.67	-0.45	-0.49	-0.75	-0.62	-0.62	0.27	-0.63	-0.65	0.37	-0.59	-0.09		-0.63	-0.65	-0.71	-0.7	-0.66	-0.61	-0.29	-0.6	-0.71	-0.63	0.11
Total Liab	0.97	0.99	0.95	0.96	0.02	0.95	0.98	0.87	-0.21	0.95	0.99	0.24	0.99	0.4	-0.63		0.97	0.71	0.94	0.86	0.99	0.74	0.97	0.84	0.98	0.61
Total Current Assets	0.98	0.99	0.97	0.93	-0.09	0.97	0.99	0.84	-0.33	0.99	0.99	0.19	0.93	0.34	-0.65	0.97		0.75	0.88	0.92	0.98	0.69	0.97	0.85	0.97	0.53
Intangible Assets	0.83	0.73	0.85	0.69	0.03	0.87	0.71	0.9	-0.42	0.73	0.71	-0.07	0.67	-0.08	-0.71	0.71	0.75		0.61	0.82	0.72	0.21	0.81	0.94	0.77	0.37
Short Long Term Debt Total	0.86	0.92	0.83	0.84	0.28	0.85	0.9	0.73	-0.22	0.85	0.91	0.21	0.93	0.47	-0.7	0.94	0.88	0.61		0.69	0.9	0.72	0.85	0.71	0.89	0.42
Other Current Liab	0.94	0.89	0.95	0.83	-0.16	0.95	0.89	0.87	-0.27	0.92	0.9	0.06	0.81	0.1	-0.66	0.86	0.92	0.82	0.69		0.88	0.46	0.93	0.91	0.88	0.45
Accounts Payable	0.98	0.99	0.96	0.95	-0.08	0.95	0.98	0.86	-0.23	0.97	0.98	0.21	0.96	0.42	-0.61	0.99	0.98	0.72	0.9	0.88		0.78	0.97	0.84	0.99	0.59
Short Term Debt	0.63	0.72	0.6	0.71	-0.08	0.57	0.72	0.46	0.06	0.68	0.71	0.26	0.74	0.73	-0.29	0.74	0.69	0.21	0.72	0.46	0.78		0.63	0.41	0.71	0.46
Property Plant And Equipment Gross	0.99	0.97	0.99	0.97	-0.1	0.97	0.95	0.93	-0.24	0.95	0.97	0.2	0.95	0.23	-0.6	0.97	0.97	0.81	0.85	0.93	0.97	0.63		0.91	0.97	0.65
Short Term Investments	0.93	0.83	0.94	0.82	0.01	0.95	0.82	0.98	-0.17	0.82	0.85	-0.02	0.83	0.05	-0.71	0.84	0.85	0.94	0.71	0.91	0.84	0.41	0.91		0.88	0.47
Inventory	0.98	0.98	0.97	0.96	-0.06	0.96	0.97	0.89	-0.24	0.95	0.97	0.16	0.96	0.38	-0.63	0.98	0.97	0.77	0.89	0.88	0.99	0.71	0.97	0.88		0.6
Other Liab	0.58	0.56	0.56	0.78	-0.4	0.48	0.54	0.6	-0.01	0.5	0.56	0.47	0.65	0.2	0.11	0.61	0.53	0.37	0.42	0.45	0.59	0.46	0.65	0.47	0.6

Click cells to compare fundamentals

Regeneron Pharmaceuticals Account Relationship Matchups

Regeneron Pharmaceuticals balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	14.8B	17.2B	25.4B	29.2B	33.1B	34.7B
Total Current Liabilities	1.8B	2.8B	3.5B	3.8B	3.4B	3.6B
Total Stockholder Equity	11.1B	11.0B	18.8B	22.7B	26.0B	27.3B
Property Plant And Equipment Net	2.9B	3.2B	3.5B	3.8B	4.2B	4.4B
Net Debt	(903.9M)	502M	(185.9M)	(404.5M)	(27.1M)	(28.5M)
Retained Earnings	7.4B	10.9B	19.0B	23.3B	27.3B	28.6B
Cash	1.6B	2.2B	2.9B	3.1B	2.7B	2.9B
Non Current Assets Total	4.2B	4.4B	4.9B	7.1B	13.6B	14.3B
Non Currrent Assets Other	531.8M	328.9M	555.2M	(4.7B)	366.1M	384.4M
Cash And Short Term Investments	6.5B	6.7B	12.5B	14.3B	10.8B	11.4B
Net Receivables	2.7B	4.1B	6.0B	5.3B	5.7B	6.0B
Common Stock Shares Outstanding	114.6M	115.1M	112.2M	113.5M	113.7M	75.4M
Liabilities And Stockholders Equity	14.8B	17.2B	25.4B	29.2B	33.1B	34.7B
Non Current Liabilities Total	1.9B	3.3B	3.2B	2.7B	3.7B	3.9B
Other Current Assets	959.3M	1.2B	664.8M	411.2M	386.6M	197.8M
Other Stockholder Equity	3.7B	102.9M	(173.4M)	(404M)	(1.2B)	(1.1B)
Total Liab	3.7B	6.1B	6.7B	6.6B	7.1B	7.5B
Total Current Assets	10.6B	12.8B	20.5B	22.1B	19.5B	20.5B
Short Long Term Debt Total	713.9M	3.6B	2.7B	2.7B	2.7B	2.8B
Other Current Liab	781.1M	122.4M	2.2B	2.1B	2.4B	2.5B
Accounts Payable	418.1M	475.5M	564M	589.2M	606.6M	636.9M
Property Plant And Equipment Gross	2.9B	3.2B	4.9B	5.4B	6.1B	6.4B
Accumulated Other Comprehensive Income	21.1M	29.3M	(26.2M)	(238.8M)	(80.9M)	(76.9M)
Short Term Investments	1.6B	1.4B	2.8B	4.6B	8.1B	8.5B
Inventory	1.4B	1.9B	2.0B	2.4B	2.6B	2.7B
Other Liab	889M	635.5M	515.3M	707.8M	814.0M	854.7M
Other Assets	910.6M	913.3M	2.8B	555.2M	747.6M	0.0
Property Plant Equipment	2.9B	3.2B	3.5B	3.8B	4.3B	4.5B
Current Deferred Revenue	591.7M	577.7M	442M	547.7M	458.9M	481.8M
Net Tangible Assets	11.1B	11.0B	18.8B	21.7B	25.0B	26.3B
Retained Earnings Total Equity	7.4B	10.9B	19.0B	23.3B	26.8B	28.1B
Long Term Debt Total	713.9M	2.0B	2.0B	2.0B	2.3B	2.4B
Capital Surpluse	4.4B	6.7B	8.1B	9.9B	11.4B	12.0B

Pair Trading with Regeneron Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Regeneron Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Regeneron Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with Regeneron Stock

0.65

ELAN

Elanco Animal Health Potential Growth

Pair Corr

Moving against Regeneron Stock

0.94	BMY	Bristol Myers Squibb Aggressive Push	Pair Corr
0.87	GILD	Gilead Sciences	Pair Corr
0.85	ESPR	Esperion Therapeutics	Pair Corr
0.79	EWTX	Edgewise Therapeutics	Pair Corr
0.74	BHC	Bausch Health Companies	Pair Corr

The ability to find closely correlated positions to Regeneron Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Regeneron Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Regeneron Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Regeneron Pharmaceuticals to buy it.

The correlation of Regeneron Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Regeneron Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Regeneron Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Regeneron Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Regeneron Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Regeneron Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Regeneron Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Regeneron Pharmaceuticals Stock:

How To Invest In Regeneron

Details

Is Regeneron Stock a good investment?

Details

What is Regeneron Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.

You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regeneron Pharmaceuticals. If investors know Regeneron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regeneron Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.298

Earnings Share

40.46

Revenue Per Share

128.691

Quarterly Revenue Growth

0.106

Return On Assets

0.0741

The market value of Regeneron Pharmaceuticals is measured differently than its book value, which is the value of Regeneron that is recorded on the company's balance sheet. Investors also form their own opinion of Regeneron Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Regeneron Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regeneron Pharmaceuticals' market value can be influenced by many factors that don't directly affect Regeneron Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Regeneron Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Regeneron Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regeneron Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Regeneron Historical Balance Sheet

Regeneron Pharmaceuticals Inventory

2.71 Billion

About Regeneron Balance Sheet Analysis

Regeneron Pharmaceuticals Balance Sheet Chart

Total Assets

Total Stockholder Equity

Property Plant And Equipment Net

Capital Stock

Regeneron Pharmaceuticals balance sheet Correlations

Regeneron Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Regeneron Pharmaceuticals balance sheet Accounts

Pair Trading with Regeneron Pharmaceuticals

Moving together with Regeneron Stock

Moving against Regeneron Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Retained Earnings	+ 0.99	Total Assets
Property Plant And Equipment Gross	+ 0.99	Total Assets
Cash	+ 0.99	Total Current Liabilities
Total Liab	+ 0.99	Total Current Liabilities
Total Current Assets	+ 0.99	Total Current Liabilities

Other Stockholder Equity	- 0.75	Retained Earnings
Short Term Investments	- 0.71	Other Stockholder Equity
Intangible Assets	- 0.71	Other Stockholder Equity
Short Long Term Debt Total	- 0.7	Other Stockholder Equity
Other Stockholder Equity	- 0.67	Total Stockholder Equity
Other Current Liab	- 0.66	Other Stockholder Equity